{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Strosberg J"],"funding":["Advanced Accelerator Applications, a Novartis Company","NCATS NIH HHS","NCI NIH HHS"],"pagination":["2372-2382"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC7396396"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["47(10)"],"pubmed_abstract":["<h4>Purpose</h4>To assess the impact of baseline liver tumour burden, alkaline phosphatase (ALP) elevation, and target lesion size on treatment outcomes with <sup>177</sup>Lu-Dotatate.<h4>Methods</h4>In the phase 3 NETTER-1 trial, patients with advanced, progressive midgut neuroendocrine tumours (NET) were randomised to 177Lu-Dotatate (every 8 weeks, four cycles) plus octreotide long-acting release (LAR) or to octreotide LAR 60 mg. Primary endpoint was progression-free survival (PFS). Analyses of PFS by baseline factors, including liver tumour burden, ALP elevation, and target lesion size, were performed using Kaplan-Meier estimates; hazard ratios (HRs) with corresponding 95% CIs were estimated using Cox regression.<h4>Results</h4>Significantly prolonged median PFS occurred with <sup>177</"],"journal":["European journal of nuclear medicine and molecular imaging"],"pubmed_title":["Impact of liver tumour burden, alkaline phosphatase elevation, and target lesion size on treatment outcomes with <sup>177</sup>Lu-Dotatate: an analysis of the NETTER-1 study."],"pmcid":["PMC7396396"],"funding_grant_id":["N/A","P30 CA008748","P30 CA086862","P50 CA174521","UL1 TR001863"],"pubmed_authors":["Baum RP","Hobday T","Seregni E","Benson A","Morse M","Reed N","Lebtahi R","Deroose CM","Hendifar A","Metz DC","Bodei L","NETTER-1 study group","Erion JL","Baudin E","Santoro P","Delpassand E","He B","Srirajaskanthan R","Caplin M","Strosberg J","Yao J","Berlin J","Grande E","Mittra E","Al-Nahhas A","Kunz PL","Gericke G","Mora J","Giammarile F","Kulke MH","Verslype C","Taieb D","Wolin E","Mariani MF","Polack BD","Ansquer C","Courbon F","Krenning E","O'Dorisio TM","Oberg K","Ravasi L","Grana CM","Severi S","Ruszniewski P","Bushnell D","Pavel M","Paganelli G"],"additional_accession":[]},"is_claimable":false,"name":"Impact of liver tumour burden, alkaline phosphatase elevation, and target lesion size on treatment outcomes with <sup>177</sup>Lu-Dotatate: an analysis of the NETTER-1 study.","description":"<h4>Purpose</h4>To assess the impact of baseline liver tumour burden, alkaline phosphatase (ALP) elevation, and target lesion size on treatment outcomes with <sup>177</sup>Lu-Dotatate.<h4>Methods</h4>In the phase 3 NETTER-1 trial, patients with advanced, progressive midgut neuroendocrine tumours (NET) were randomised to 177Lu-Dotatate (every 8 weeks, four cycles) plus octreotide long-acting release (LAR) or to octreotide LAR 60 mg. Primary endpoint was progression-free survival (PFS). Analyses of PFS by baseline factors, including liver tumour burden, ALP elevation, and target lesion size, were performed using Kaplan-Meier estimates; hazard ratios (HRs) with corresponding 95% CIs were estimated using Cox regression.<h4>Results</h4>Significantly prolonged median PFS occurred with <sup>177</","dates":{"release":"2020-01-01T00:00:00Z","publication":"2020 Sep","modification":"2026-05-02T21:38:34.749Z","creation":"2020-08-17T07:11:30Z"},"accession":"S-EPMC7396396","cross_references":{"pubmed":["32123969"],"doi":["10.1007/s00259-020-04709-x"]}}